Evidence map›Paper›PMID 36987921›Full record

ArticleJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research2023

Multi-Targeting DKK1 and LRP6 Prevents Bone Loss and Improves Fracture Resistance in Multiple Myeloma.

Marija K Simic, Sindhu T Mohanty, Ya Xiao, Tegan L Cheng, Victoria E Taylor, Olga Charlat, Peter I Croucher, Michelle M McDonald

Open access · hybridAbstract read
In one paragraph

Article in Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Incidence of first and subsequent fractures in multiple myeloma patients: a parallel cohort study using UK CPRD dataset.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026
    Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Early and multiple doses of zoledronate mitigates rebound bone loss following withdrawal of receptor activator of nuclear factor kappa-B ligand inhibition.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2025
    Article
  13. Article
  14. Halofuginone Inhibits Osteoclastogenesis and Enhances Osteoblastogenesis by Regulating Th17/Treg Cell Balance in Multiple Myeloma Mice with Bone Lesions.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2024
    Article
  15. Severe Osteoporosis With PathogenicJCEM case reports · 2024
    Article
  16. Article
  17. Doubling Down on Wnt Signaling to Overcome Myeloma Bone Disease.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2023
    Article
  18. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Marija K SimicSkeletal Diseases Program, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.ORCID 0000-0001-9374-3599
Sindhu T MohantySkeletal Diseases Program, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.
Ya XiaoSkeletal Diseases Program, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.
Tegan L ChengCentre for Children's Bone and Musculoskeletal Health, The Children's Hospital at Westmead, Westmead, NSW, Australia.ORCID 0000-0002-4208-7242
Victoria E TaylorSkeletal Diseases Program, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.
Olga CharlatNovartis Institutes for Biomedical Research, Cambridge, MA, USA.
Peter I CroucherSkeletal Diseases Program, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.ORCID 0000-0002-7102-2413
Michelle M McDonaldSkeletal Diseases Program, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.ORCID 0000-0002-3928-2506
Garvan Institute of Medical Research · AUChildren's Hospital at Westmead · AUNovartis (United States) · USThe University of Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An imbalance between bone resorption and bone formation underlies the devastating osteolytic lesions and subsequent fractures seen in more than 90% of multiple myeloma (MM) patients. Currently, Wnt-targeted therapeutic agents that prevent soluble antagonists of the Wnt signaling pathway, sclerostin (SOST) and dickkopf-1 (DKK1), have been shown to prevent bone loss and improve bone strength in preclinical models of MM. In this study, we show increasing Wnt signaling via a novel anti-low-density lipoprotein receptor-related protein 6 (LRP6) antibody, which potentiates Wnt1-class ligand signaling through binding the Wnt receptor LRP6, prevented the development of myeloma-induced bone loss primarily through preventing bone resorption. When combined with an agent targeting the soluble Wnt antagonist DKK1, we showed more robust improvements in bone structure than anti-LRP6 treatment alone. Micro-computed tomography (μCT) analysis demonstrated substantial increases in trabecular bone volume in naïve mice given the anti-LRP6/DKK1 combination treatment strategy compared to control agents. Mice injected with 5TGM1eGFP murine myeloma cells had significant reductions in trabecular bone volume compared to naïve controls. The anti-LRP6/DKK1 combination strategy significantly improved bone volume in 5TGM1-bearing mice by 111%, which was also superior to anti-LRP6 single treatment; with similar bone structural changes observed within L

Indexed as

Intercellular Signaling Peptides and ProteinsLow Density Lipoprotein Receptor-Related Protein-6Multiple MyelomaOsteolysisAnimalsAntibodiesBone and BonesCell Line, TumorFemaleMiceMice, Inbred C57BLWnt Signaling PathwayAntibodiesDkk1 protein, mouseIntercellular Signaling Peptides and ProteinsLow Density Lipoprotein Receptor-Related Protein-6BONEDKK1LRP6MYELOMAWNT

Identifiers

PMID36987921
PMCPMC10947379
OpenAlexW4361198760

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.